Amgen (AMGN) acquires dark Blue Therapeutics for up to USD 840mln, bolstering Oncology pipeline

Amgen's acquisition of Dark Blue Therapeutics for up to $840 million is a strategic move to enhance its oncology pipeline.

Newsquawk StaffNewswiresPublished On the live feed at 6 more headlines followed before this page went public
Newsquawk headlinesUTC

Caterpillar (CAT) introduces Cat AI assistant and is to launch in Q1 2026

Amazon's (AMZN) Alexa+ announces plans to expand to Samsung TV (005930 KS), BMW (BMW GY) and many more

Amgen (AMGN) acquires dark Blue Therapeutics for up to USD 840mln, bolstering Oncology pipeline

European Commission President von der Leyen is proposing early access to agricultural funds in the 2028 EU budget to assist farmers, according to a letter

Dell (DELL) introducing Dell ultrasharp 52 thunderbolt hub monitor AND Dell ultrasharp 32 4k qd-oled monitor

Open the platform and use it. The whole workspace is free to try, with no signup and no card. When you want the headlines arriving live instead of on a delay, Newsquawk Pro is £24.99 for 7 days.

Free. No signup, no card.
Context

This deal signals Amgen's continued commitment to expanding its portfolio in a high-growth sector, which could positively influence investor sentiment and lead to potential market gains within the biotech space. Watch for how this acquisition may impact Amgen's stock performance and any ripple effects on sector peers.

Related headlines

The whole workspace, free to try.

Try it free